BridgeBio Pharma Pre-Tax Profit Margin 2018-2025 | BBIO

BridgeBio Pharma pre-tax profit margin for the quarter ending March 31, 2025 was -528.13%.

  • BridgeBio Pharma average pre-tax profit margin for 2024 was -227.14%, a 96.06% increase from 2023.
  • BridgeBio Pharma average pre-tax profit margin for 2023 was -5766.86%, a 782.17% decline from 2022.
  • BridgeBio Pharma average pre-tax profit margin for 2022 was -653.71%, a 28.24% increase from 2021.

Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue.

BridgeBio Pharma Pre-Tax Profit Margin 2018-2025 | BBIO

  • BridgeBio Pharma average pre-tax profit margin for 2024 was -227.14%, a 96.06% increase from 2023.
  • BridgeBio Pharma average pre-tax profit margin for 2023 was -5766.86%, a 782.17% decline from 2022.
  • BridgeBio Pharma average pre-tax profit margin for 2022 was -653.71%, a 28.24% increase from 2021.

Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue.
Related Stocks
Company NameMarket
Cap
Teva Pharmaceutical Industries (TEVA)$15.5B
Dr Reddy's Laboratories (RDY)$11.4B
Bausch Health Cos (BHC)$1.9B
Supernus Pharmaceuticals (SUPN)$1.7B
Amphastar Pharmaceuticals (AMPH)$1.1B
Personalis (PSNL)$282M
Taysha Gene Therapies (TSHA)$254M
Assembly Biosciences (ASMB)$75M
Sol-Gel Technologies (SLGL)$15M
Evoke Pharma (EVOK)$3M
Teligent (TLGT)$0M